Advertisement
A conference call to review the results will begin at 4:30 p.m. ET (1:30p.m. PT) on November 14, 2007 and will be hosted by Anthony DiTonno, Presidentand Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.
Advertisement
The conference call dial-in numbers are 1-877-407-0789 (USA) or1-201-689-8562 (International). In addition, a dial-up replay of theconference call will be available beginning November 14, 2007 at 7:30 p.m. ET(4:30 p.m. PT) and ending on November 28, 2007. The replay telephone number is1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055,Conference ID Number: 261580.
A live web cast of the call will also be available from the InvestorRelations section on the corporate web site at http://www.neurogesx.com. A webcast replay can be accessed on the corporate web site beginning November 14,2007 at approximately 6:00 p.m. ET. The replay will remain available untilDecember 14, 2007.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused ondeveloping and commercializing novel pain management therapies. Its initialfocus is on chronic peripheral neuropathic pain, including postherpeticneuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) andpainful diabetic neuropathy. NeurogesX' late stage product portfolio is led byits product candidate NGX-4010, a dermal patch designed to manage painassociated with peripheral neuropathic pain conditions, that the companybelieves offers significant advantages over other pain therapies. Three Phase3 clinical trials with NGX-4010 have been completed and have met their primaryendpoints, two in PHN and one in HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). NeurogesXdisclaims any intent or obligation to update these forward-looking statements,and claims the protection of the Safe Harbor for forward-looking statementscontained in the Act. Examples of such statements include, but are not limitedto, the timing of presentations by NeurogesX and the expected benefits ofNeurogesX' potential products, including its lead product candidate NGX-4010.Such statements are based on management's current expectations, but actualresults may differ materially due to various risks and uncertainties,including, but not limited to, past results of clinical trials may not beindicative of future clinical trials results; NeurogesX' product candidate mayhave unexpected adverse side effects or inadequate therapeutic efficacy;positive results in clinical trials may not be sufficient to obtain FDA orEuropean regulatory approval; physician or patient reluctance to use NGX-4010,if approved, or the inability of physicians to obtain sufficient reimbursementfor such procedures; potential alternative therapies; maintaining adequatepatent or trade secret protection without violating the intellectual propertyrights of others; and other difficulties or delays in clinical development,obtaining regulatory approval, market acceptance and commercialization ofNGX-4010 and the advantages of NGX-4010 over other pain therapies. For furtherinformation regarding these and other risks related to NeurogesX' business,investors should consult NeurogesX' filings with the Securities and ExchangeCommission.NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Investors / Media (650) 358-3300 Stephanie Carrington / Jason Rando (646) 536-7017 / 7025
